心血管预防与人群健康的精准医学:是否遥不可及?
该综述探讨精准医学在心血管预防和人群健康中的应用前景。目前精准工具有限,但通过遗传学、循环生物标志物和影像学改进风险评估,可实现结局特异性风险预测和增强表型分析,从而指导个体或群体的个性化管理,改善成本效益和风险获益。
要点
- 现有风险评估工具粗糙且性能有限,精准医学进展缓慢。
- 遗传学、生物标志物和影像学有望改进风险评估和表型分析。
- 个性化管理可匹配治疗与风险特征,提升成本效益和风险获益。
核心结论
- 精准医学在心血管预防和人群健康中潜力巨大,但当前可用工具有限,需进一步创新以指导评估和管理。
研究设计与样本
- 综述性文章,探讨精准医学方法在心血管预防和人群健康中的应用、可用工具及未来展望。
主要发现
- 心血管预防和人群健康已有风险评估基础,但现有工具粗糙且性能边际。
- 遗传学、循环生物标志物和影像学可能改善风险评估,实现结局特异性风险预测和增强表型分析。
临床怎么用
- 可基于改进的风险评估工具,为个体或群体匹配个性化治疗,以改善成本效益和风险获益。
局限性
- 目前精准工具有限,进展缓慢,临床可用性不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these areas are already informed by risk-assessment, but limited by the use of crude assessment tools with marginal performance. Risk assessment in prevention and population health may be improved with the use of genetics, circulating biomarkers, and imaging, leading to outcome-specific risk-prediction and enhanced phenotyping. Personalized management matching therapy to risk profile can be then implemented for either individuals or groups, improving cost-effectiveness and risk-benefit. Here, we explore this precision-like approach, including available tools, potential applications, and future perspectives for cardiovascular prevention and population health management.
引用
- Giugni FR, Berry JD, Khera A, et al. Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far? Circulation. 2024. PMID: 39556656. doi:10.1161/CIRCULATIONAHA.124.070081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。